← Back
Data updated: Mar 10, 2026
PARKE DAVIS
NeurologyInfectious DiseaseDermatology
PARKE DAVIS is a major pharmaceutical company focused on Neurology, Infectious Disease, Dermatology.
1953
Since
74
Drugs
-
Trials
134
Approved (2yr)
Key Drugs
No active drugs
Recent Activity
HEPARIN SODIUM 2026-02-20
Labeling
HEPARIN SODIUM 2026-02-20
Labeling
MEPERIDINE HYDROCHLORIDE 2025-12-22
Labeling
MEPERIDINE HYDROCHLORIDE 2025-12-22
Labeling
MEPERIDINE HYDROCHLORIDE 2025-12-22
Labeling
MEPERIDINE HYDROCHLORIDE 2025-12-22
Labeling
MEPERIDINE HYDROCHLORIDE 2025-12-22
Labeling
MEPERIDINE HYDROCHLORIDE 2025-12-22
Labeling
MEPERIDINE HYDROCHLORIDE 2025-12-22
Labeling
MEPERIDINE HYDROCHLORIDE 2025-12-22
Labeling
SEC Filings
Pro
Loading...
Therapeutic Focus
Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5
Neurology 57%
4 drugs
Infectious Disease 29%
2 drugs
Dermatology 14%
1 drugs
Pipeline Strength Pro
Loading...
Competitors Pro
Discontinued (66)
HEPARIN SODIUM MEPERIDINE HYDROCHLORIDE ISOPROTERENOL HYDROCHLORIDE DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE METHYLTESTOSTERONE INDOMETHACIN HYDROCORTISONE THIAMINE HYDROCHLORIDE HEPARIN LOCK FLUSH METHYLDOPA CHLORDIAZEPOXIDE HYDROCHLORIDE ERYTHROMYCIN ETHYLSUCCINATE METHYLDOPA AND HYDROCHLOROTHIAZIDE PENICILLIN G POTASSIUM ERYC NITROSTAT CELONTIN MEPROBAMATE TOLBUTAMIDE CHLOROMYCETIN HUMATIN HYDROCORTISONE ACETATE TRIPELENNAMINE HYDROCHLORIDE FEMPATCH ELASE-CHLOROMYCETIN ISOETHARINE HYDROCHLORIDE PROCAN SR CENTRAX ESTROVIS SODIUM PENTOBARBITAL SECOBARBITAL SODIUM MECLOMEN SPIRONOLACTONE W/ HYDROCHLOROTHIAZIDE UTICORT PROMAPAR PARACORT ERYPAR MILONTIN SULFALAR NORLUTATE ERYC 125 AMBODRYL NORLUTIN UTIMOX NORLESTRIN 28 1/50 NORLESTRIN FE 2.5/50 PROCAN BENYLIN PITRESSIN TANNATE PARSIDOL
+16 more
Company Info
- First Approval
- 1953-09-08
- Latest
- 2022-04-28
- Applications
- 105